HRP20020994A2 - Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus - Google Patents
Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus Download PDFInfo
- Publication number
- HRP20020994A2 HRP20020994A2 HR20020994A HRP20020994A HRP20020994A2 HR P20020994 A2 HRP20020994 A2 HR P20020994A2 HR 20020994 A HR20020994 A HR 20020994A HR P20020994 A HRP20020994 A HR P20020994A HR P20020994 A2 HRP20020994 A2 HR P20020994A2
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- dipeptidyl peptidase
- insulin
- benzyl
- Prior art date
Links
- 239000003472 antidiabetic agent Substances 0.000 title claims description 29
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 27
- 229940125708 antidiabetic agent Drugs 0.000 title claims description 22
- 239000003112 inhibitor Substances 0.000 title description 18
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 235000019833 protease Nutrition 0.000 title 1
- 238000000034 method Methods 0.000 claims description 31
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 22
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 22
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims description 21
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 21
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims description 16
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 16
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 16
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 12
- -1 5-cyanopyridine -2-yl Chemical group 0.000 claims description 11
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 11
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 11
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 11
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 229940123208 Biguanide Drugs 0.000 claims description 9
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 7
- 229940100389 Sulfonylurea Drugs 0.000 claims description 7
- 230000003178 anti-diabetic effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229960005095 pioglitazone Drugs 0.000 claims description 6
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 6
- 229960004580 glibenclamide Drugs 0.000 claims description 5
- NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 claims description 5
- 229950008402 glisentide Drugs 0.000 claims description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 5
- 229960003105 metformin Drugs 0.000 claims description 5
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 4
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 4
- 125000004060 L-alloisoleucine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 4
- 229960002632 acarbose Drugs 0.000 claims description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 4
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical class C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000346 gliclazide Drugs 0.000 claims description 4
- 229960004346 glimepiride Drugs 0.000 claims description 4
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 4
- 229960001381 glipizide Drugs 0.000 claims description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 4
- 229960002277 tolazamide Drugs 0.000 claims description 4
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 4
- 229960005371 tolbutamide Drugs 0.000 claims description 4
- 229960001641 troglitazone Drugs 0.000 claims description 4
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 4
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical group C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 3
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 3
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 3
- 229960001761 chlorpropamide Drugs 0.000 claims description 3
- 229950000269 emiglitate Drugs 0.000 claims description 3
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 claims description 3
- 229960001110 miglitol Drugs 0.000 claims description 3
- 229960000698 nateglinide Drugs 0.000 claims description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 3
- 229960002354 repaglinide Drugs 0.000 claims description 3
- 229960001729 voglibose Drugs 0.000 claims description 3
- XGNBIYXILDDDQR-DTWKUNHWSA-N (2s)-1-[(2s)-2-amino-3,3-dimethylbutanoyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)(C)[C@H](N)C(=O)N1CCC[C@H]1C#N XGNBIYXILDDDQR-DTWKUNHWSA-N 0.000 claims description 2
- ZHUTVLURGLOKMO-ZETCQYMHSA-N (2s)-1-acetylpyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CCC[C@H]1C#N ZHUTVLURGLOKMO-ZETCQYMHSA-N 0.000 claims description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001466 acetohexamide Drugs 0.000 claims description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims description 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 2
- 150000004283 biguanides Chemical class 0.000 claims description 2
- 229960004111 buformin Drugs 0.000 claims description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003362 carbutamide Drugs 0.000 claims description 2
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229950009226 ciglitazone Drugs 0.000 claims description 2
- 229950002375 englitazone Drugs 0.000 claims description 2
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 229960003243 phenformin Drugs 0.000 claims description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- PDPBIXXIHOWWHA-UHFFFAOYSA-N 2-benzyl-3,4-dihydro-2h-chromene Chemical compound C1CC2=CC=CC=C2OC1CC1=CC=CC=C1 PDPBIXXIHOWWHA-UHFFFAOYSA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229960001764 glibornuride Drugs 0.000 claims 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 claims 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 claims 1
- 229950005319 glisolamide Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 42
- 238000002360 preparation method Methods 0.000 description 29
- 239000013543 active substance Substances 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 6
- 230000002641 glycemic effect Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- ZSOPWZQRZHWYFY-NUXPJIRBSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(e)-but-2-enedioic acid Chemical group OC(=O)\C=C\C(O)=O.CC[C@H](C)[C@H](N)C(=O)N1CCSC1 ZSOPWZQRZHWYFY-NUXPJIRBSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 229940096516 dextrates Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- UTDVHCQTKWTQEA-UHFFFAOYSA-N 1-(2-aminoacetyl)-n-(4-methyl-2-oxochromen-7-yl)pyrrolidine-2-carboxamide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1NC(=O)C1CCCN1C(=O)CN UTDVHCQTKWTQEA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229960003236 glisoxepide Drugs 0.000 description 1
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Ovaj izum odnosi se na postupak liječenja, posebice na postupak liječenja dijabetesa melitusa, naročito dijabetesa neovisnog o inzulinu (NIDDM) ili dijabetesa tipa 2 i stanja povezanih s dijabetesom melitusom, te na pripravke za primjenu u navedenom postupku.
Dipeptidil peptidaza IV (DPP-IV) je serinska proteaza koja cijepa protein iza prolina ili alanina nađena u različitim tjelesnim tkivima uključujući tkiva bubrega, jetre i crijeva.
Poznato je da inhibitori DPP-IV mogu biti korisni za liječenje smanjene tolerancije na glukozu i dijabetesa melitusa (Međunarodna patentna prijava, broj publikacije W099/61431, Pederson RA et al,. Diabetes. 1998 Aug; 47 (8): 1253-8 and Pauly RP et al, Metabolism 1999 Mar; 48 (3): 385-9). Naročito publikacija W099/61431 otkriva inhibitore DPP IV koji sadrže aminokiselinu i tiazolidinsku ili pirolidinsku grupu te njihove soli, kao što je izoleucil (ili izoleucin) tiazolidid i njegove soli.
Drugi inhibitori DPP-IV uključuju one obznanjene u US patentima broj 6124305 i US 6107317, Međunarodne patentne prijave, brojevi publikacija WO 9819998, WO 9515309 i WO 9818763.
Antihiperglikemici inhibitori alfa glukozidaze (ili inhibitori alfa glukozidaze) i bigvanidni antihiperglikemici (ili bigvanidi) uobičajeno se rabe u liječenju dijabetesa tipa 2. Akarboza, vogliboza, emiglitat i miglitol su primjeri inhibitora alfa glukozidaze. 1, 1-dimetilbigvanidin (ili metformin) je poseban primjer bigvanida.
Inzulinski sekretagogi su spojevi koji potiču povećanu sekreciju inzulina iz beta stanica gušterače. Sulfonilureje su dobro poznati primjeri inzulinskih sekretagoga. Sulfonilureje djeluju kao hipoglikemici i rabe se u liječenju dijabetesa tipa 2. Primjeri sulfonilureja uključuju glibenklamid (ili gliburid), glipizid, gliklazid, glimepirid, tolazamid i tolbutamid.
Europska patentna prijava, broj publikacije 0,306,228 odnosi se na određene derivate tiazolidindiona za koje je otkriveno da imaju antihiperglikemično i hipolipidemično djelovanje. Jedan poseban tiazolidindion obznanjen u EP 0306228 je 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil]tiazolidin-2,4-dion (nadalje Spoj (I)).
W094/05659 otkriva određene soli Spoja (I) uključujući maleat u primjeru 1 navedene publikacije.
Spoj (I) je primjer klase antihiperglikemika poznatih kao “inzulinski senzitizatori”. Posebice je Spoj (I) tiazolidindionski inzulinski senzitizator. Spoj (I) je također inzulinski senzitizator agonista aktiviranog proliferatorom peroksisoma (PPARγ).
Europske patentne prijave, brojevi publikacija: 0008203, 0139421, 0032128, 0428312, 0489663, 0155845, 0257781, 0208420, 0177353, 0319189, 0332331, 0332332, 0528734,0508740; Međunarodne patentne prijave, brojevi publikacija 92/18501, 93/02079,93/22445 i US brojevi patenata 5104888 i 5478852, također otkrivaju određene tiazolidindionske inzulinske senzitizatore.
Druge serije spojeva općenito prepoznatih da imaju djelovanje kao inzulinski senzitizatori su predočeni kao spojevi obznanjeni u Međunarodnim patentnim prijavama, brojevi publikacija W093/21166 i W094/01420. Ovi spojevi se nadalje nazivaju 'aciklički inzulinski senzitizatori'. Ostali primjeri acikličkih inzulinskih senzitizatora su oni obznanjeni u US patentu broj 5232945 i Međunarodnim patentnim prijavama, brojevi publikacija W092/03425 i W091/19702.
Primjeri ostalih inzulinskih senzitizatora su obznanjeni u Europskoj patentnoj prijavi, broj publikacije 0533933, Japanskoj patentnoj prijavi broj publikacije 05271204 i US patent broj 5264451.
Gore spomenute publikacije ovdje su uključene kao reference.
Ovdje je naznačeno da inhibitori dipeptidil peptidaze IV kao što su spojevi iz publikacije W099/61431, u kombinaciji s ostalim antidijabeticima osiguravaju posebno koristan učinak na kontrolu glikemije, te je sugerirano da je takva kombinacija posebno korisna za liječenje dijabetesa melitusa, naročito dijabetesa tipa 2 i stanja povezanih s dijabetesom melitusom. Takva kombinacija će osigurati bolju regulaciju glukoze u krvi bez uvođenja neprihvatljivih nus pojava.
Prema tome, izum osigurava postupak za liječenje dijabetesa melitusa, naročito dijabetesa tipa 2 i stanja povezanih s dijabetesom melitusom kod sisavaca kao što je čovjek, a koji se sastoji od primjene učinkovitih, netoksičnih i farmaceutski prihvatljivih količina inhibitora dipeptidil peptidaze IV i drugog antidijabetika, sisavcima kojima je to potrebno.
U slijedećem aspektu ovaj izum osigurava inhibitor dipeptidil peptidaze IV i drugi antidijabetik za primjenu u postupku liječenja dijabetesa melitusa, naročito dijabetesa tipa 2 i stanja povezanih s dijabetesom melitusom.
Postupak obuhvaća zajedničku primjenu inhibitora dipeptidil peptidaze IV i drugog antidijabetika ili njihovo uzastopno davanje.
Zajednička primjena uključuje primjenu formulacije koja sadržava i inhibitor DPP-IV i drugi antidijabetik ili uglavnom istovremenu primjenu odvojenih formulacija svake od tvari.
U slijedećem aspektu ovaj izum osigurava uporabu inhibitora dipeptidil peptidaze IV i drugog antidijabetika u proizvodnji pripravka za liječenje pretilosti, dijabetesa melitusa, naročito dijabetesa tipa 2 i stanja povezanih s dijabetesom melitusom.
Prikladno, drugi antidijabetik obuhvaća jedan ili više, obično jedan ili dva, inhibitora alfa glukozidaze, bigvanid, inzulinski sekretagog ili inzulinski senzitizator.
Prikladno, drugi antidijabetik izabran je iz skupine koju čine inhibitor alfa glukozidaze, bigvanid, inzulinski sekretagog ili inzulinski senzitizator.
Slijedeći prikladan antidijabetik je inzulin.
Prikladni inhibitor alfa glukozidaze je akarboza.
Ostali prikladni inhibitori alfa glukozidaze su emiglitat i miglitol. Slijedeći prikladan inhibitor alfa glukozidaze je vogliboza.
Prikladan bigvanid uključuje metformin, buformin ili fenformin, naročito metformin.
Prikladan inzulinski sekretagog uključuje sulfonilureje.
Prikladne sulfonilureje uključuju glibenklamid, glipizid, gliklazid, glimepirid, tolazamid i tolbutamid. Nadalje sulfonilureje uključuju acetoheksamid, karbutamid, klorpropamid, glibornurid, glikvidon, glizentid, glizolamid, glizoksepid, gliklopiamid i glicilamid. Također je uključena sulfonilureja glipentid.
Slijedeći prikladan inzulinski sekretagog je repaglinid. Dodatni inzulinski sekretagog je nateglinid.
Inzulinski senzitizatori uključuju inzulinske senzitizatore agonista PPARγ uključujući spojeve obznanjene u publikaciji WO 97/31907 i naročito 2-(1-karboksi-2-{4-{2-(5-metil-2-fenil-oksazol-4-il)-etoksi]-fenil}-etilamino)-metil ester benzojeve kiseline i 2(S)-(2-benzoil-fenilamino)-3-{4-[2-(5-metil-2-fenil-oksazol-4-il)-etoksi]-fenil}-propionsku kiselinu.
Inzulinski senzitizatori također uključuju tiazolidindionske inzulinske senzitizatore.
Pogodan inzulinski senzitizator je Spoj (I) ili njegov derivat.
Ostali prikladni tiazolidindionski inzulinski senzitizatori uključuju (+)-5-[[4-[(3,4-dihidro-6-hidroksi-2,5,7,8-tetrametil-2H-1-benzopiran-2-il)methoxi]fenil]metil]-2,4-tiazolidindion (ili troglitazon), 5-[4-[(1-metilcikloheksil)metoksi] benzil]tiazolidin-2,4-dione (ili ciglitazon), 5-[4-[2-(5-etilpiridin-2-il)etoksi]benzil]tiazolidin-2,4-dione (ili pioglitazon) ili 5-[(2-benzil-2,3-dihidrobenzopiran)-5ilmetil) tiazolidin-2,4-dion (ili englitazon).
Posebni tiazolidindionski inzulinski senzitizator je 5-[4-[2-(5-etilpiridin-2-il)etoksi]benzil]tiazolidin-2,4-dion (ili pioglitazon).
Posebni tiazolidindionski inzulinski senzitizator je (+)-5-[[4-[(3,4-dihidro-6-hidroksi-2,5,7,8-tetrametil-2H-1-benzopiran-2-il)metoksi]fenil]metil]-2,4-tiazolidindion (ili troglitazon).
Posebni inhibitori DPP-IV uključuju specifične primjere obznanjene u publikaciji W099/61431, kao što su L-treo-izoleucil pirolidid, L-alo-izoleucil tiazolidid, L-alo-izoleucil pirolidid i njihove soli. Posebni inhibitor DPP-IV je izoleucin tiazolidid i njegove soli.
Daljnji inhibitori DPP-IV uključuju specifične primjere obznanjene u US patentima broj 6124305 i US 6107317, Međunarodnim patentnim prijavama, brojevi publikacija WO 9819998, WO 9515309 i WO 9818763 ; kao što su 1[2-[(5-cijanopiridin-2-il)aminoetilamino]acetil-2-cijano-(S)-pirolidin i (2S)-1-[(2S)-2-amino-3,3-dimetilbutanoil]-2-pirolidinkarbonitril.
Za izbjegavanje sumnje, primjeri obznanjeni u svakoj od gore spomenutih publikacija specifično su uključeni kao reference, kao pojedinačno obznanjeni spojevi.
Podrazumijeva se da su inhibitor DPP-IV i drugi antidijabetik davani u farmaceutski prihvatljivom obliku, uključujući farmaceutski prihvatljive derivate kao što su njihove farmaceutski prihvatljive soli, esteri i solvati, prikladne za relevantnu djelatnu tvar. U nekim ovdje navedenim primjerima, imena korištena za druge antidijabetike mogu se odnositi na određeni farmaceutski oblik relevantne djelatne tvari: Podrazumijeva se da su ovim izumom obuhvaćeni svi farmaceutski prihvatljivi oblici djelatne tvari za sebe.
Prikladni farmaceutski prihvatljivi oblici antidijabetika ovise o tome koja se djelatna tvar koristi, ali uključuju poznate farmaceutski prihvatljive oblike izabrane tvari. Takvi derivati su pronađeni ili citirani u standardnim referentnim tekstovima kao što su Britanska i Američka farmakopeja, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (na primjer vidjeti 31. izdanje stranica 341 i tamo citirane stranice) ili gore spomenute publikacije.
Prikladni farmaceutski prihvatljivi oblici inhibitora DPP-IV uključuju soli i solvate, uključujući one opisane u publikaciji WO 99/61431, na primjer fumarat.
Inhibitor DPP-IV pripravljen je u skladu s objavljenim metodama, na primjer kada je inhibitor DPP-IV spoj iz publikacije WO 99/61431 ili njegov derivat, kao što je njegova farmaceutski prihvatljiva sol ili njegov farmaceutski prihvatljiv solvat, tada se pripravlja u skladu s tamo obznanjenim metodama. Slično je za spojeve iz US patenata broj 6124305 i US 6107317 i one iz Međunarodnih patentnih prijava, brojevi publikacija WO 9819998, WO 9515309 i WO 9818763.
Neki od ovdje spomenutih spojeva mogu sadržavati jedan ili više kiralnih ugljikovih atoma te tako mogu postojati u dvije ili više izomernih formi, koje su sve obuhvaćene ovim izumom, kao pojedinačni izomeri ili kao smjese izomera, uključujući racemate. Neki od ovdje spomenutih spojeva, posebice tiazolidindioni kao što je Spoj (I), koji mogu postojati u jednoj od nekoliko tautomernih formi, obuhvaćeni su ovim izumom kao pojedinačne tautomerne forme ili njihove smjese.
Inhibitor DPP-IV i drugi antidijabetik po izboru pripravljeni su u skladu s poznatim metodama, a koje su pronađene ili citirane u standardnim referentnim tekstovima, kao što su Britanska i Američka farmakopeja, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (na primjer vidjeti 31. izdanje stranica 341 i tamo citirane stranice) ili gore spomenute publikacije.
Kada se ovdje rabi pojam “stanja povezana sa dijabetesom” on uključuje stanja povezana s pre-dijabetičkim stanjem, stanjima povezanim sa samim dijabetesom melitusom i komplikacije povezane s dijabetesom melitusom.
Kada se ovdje rabi pojam “stanja povezana s pre-dijabetičkim stanjem”' on uključuje stanja kao što su inzulinska rezistencija, uključujući nasljednu inzulinsku rezistenciju, smanjenu toleranciju na glukozu i hiperinzulinemiju.
“Stanja povezana sa samim dijabetesom melitusom” uključuju hiperglikemiju, inzulinsku rezistenciju, uključujući stečenu inzulinsku rezistenciju i pretilost. Slijedeća stanja povezana sa samim dijabetesom melitusom uključuju hipertenziju i bolesti kardiovaskularnog sustava, naročito aterosklerozu i stanja povezana sa inzulinskom rezistencijom. Stanja povezana sa inzulinskom rezistencijom uključuju sindrom policističnih jajnika, inzulinsku rezistenciju induciranu steroidima te dijabetes u trudnoći.
“Stanja povezana s dijabetesom melitusom” uključuju bubrežne bolesti, naročito bubrežne bolesti povezane s dijabetesom tipa 2, neuropatiju i retinopatiju.
Bubrežne bolesti povezane s dijabetesom tipa 2 uključuju nefropatiju, glomerulonefritis, glomerularnu sklerozu, nefrotički sndrom, hipertenzivna nefroskleroza i posljednji stadij bubrežne bolesti.
Pojam “farmaceutski prihvatljivo” kao što se ovdje rabi, obuhvaća i humanu i veterinarsku primjenu: na primjer pojam “farmaceutski prihvatljivo” obuhvaća veterinarski prihvatljiv spoj.
Pod pojmom dijabetes melitus najčešće se misli na dijabetes tipa 2.
Prikladno, posebno koristan učinak na kontrolu glikemije osiguran postupkom liječenja navedenom u izumu, ima poboljšan terapijski odnos za kombinaciju iz ovog izuma, u odnosu na jedan spoj iz kombinacije, kada se koristi sam i u dozi koja osigurava učinkovitost ekvivalentnu kombinaciji iz ovog izuma.
U preferiranom aspektu, naznačeno je da je posebno koristan učinak na kontrolu glikemije, osiguran postupkom liječena opisanom u izumu, sinergistički učinak u odnosu na očekivani iz učinaka pojedinih djelatnih tvari.
U slijedećem aspektu ovog izuma, kombinirane doze inhibitora DPP-IV i drugog antidijabetika proizvest će veći koristan učinak nego što se može postići za svaku pojedinu tvar u dozi dvostrukoj od korištene za tu tvar u kombinaciji.
Kontrola glikemije može biti karakterizirana uporabom konvencionalnih metoda, na primjer mjerenjem uobičajeno korištenog indeksa kontrole glikemije kao što je razina glukoze u plazmi nakon gladovanja ili glikolizirani hemoglobin (Hb Alc). Takve vrijednosti određene su uporabom standardne metodologije, na primjer one opisane u: Tuescher A, Richterich, P.,Schweiz. med. Wschr. 101 (1971), 345 and 390 and Frank P.,'Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements', Clinical Products 1988.
U preferiranom aspektu, doza svake od djelatnih tvari, kada se primjenjuje u skladu s postupkom liječenja opisanom u izumu, bit će manja od zahtjevanih iz čistog aditivnog efekta u kontroli glikemije.
Također se smatra da će postupak liječenja opisan u izumu utjecati na poboljšanje, u odnosu na pojedine tvari, razine ubrzanja glikozilacije konačnih produkata (AGEs) i serumskih lipida koji uključuju ukupni kolesterol, HDL-kolesterol, LDL-kolesterol, uključujući poboljšanja u njihovom međusobnom omjeru, posebice poboljšanja kod serumskih lipida koji uključuju ukupni kolesterol, HDL-kolesterol, LDL-kolesterol, uključujući poboljšanja u njihovom međusobnom odnosu.
U postupku liječenja opisanom u izumu, ljekovite tvari se pogodno primjenjuju u obliku farmaceutskog pripravka. Kao što je gore navedeno, takvi pripravci mogu uključivati više ljekovitih tvari ili samo jednu.
Prema tome, ovaj izum u jednom aspektu također osigurava farmaceutski pripravak koji sadrži inhibitor dipeptidil peptidaze IV i drugi antidijabetik te farmaceutski prihvatljiv nosač.
Stoga, u slijedećem aspektu izum također osigurava postupak dobivanja farmaceutskog pripravka koji sadrži inhibitor dipeptidil peptidaze IV, drugi antidijabetik i farmaceutski prihvatljiv nosač, a koji obuhvaća miješanje inhibitora dipeptidil peptidaze IV, drugog antidijabetika i farmaceutski prihvatljivog nosača.
Pogodno je da su pripravci u jediničnom obliku u količini prikladnoj za relevantno dnevno doziranje.
Prikladno doziranje, uključujući naročito jedinično doziranje inhibitora DPP-IV i drugog antidijabetika uključuje poznata doziranja uključujući jedinične doze ovih spojeva kako je opisano ili citirano u referentnom tekstu kao što je Britanska i Američka farmakopeja, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (na primjer vidjeti 31. izdanje stranicu 341 i tamo citirane stranice) ili gore spomenute publikacije.
Stoga, prikladna doziranja za inhibitor DPP-IV navedena u WO 99/61431 i uključivo doziranja tamo otkrivena, na primjer 0.01 do 30 mg na dan ili 0.01 do 10 mg po kilogramu tjelesne mase. Također, prikladne doze drugih ovdje spomenutih inhibitora DPP-IV uključuju one spomenute u gore navedenim relevantnim publikacijama.
Za inhibitor alfa glukozidaze, prikladna količina akarboze je u području od 25 to 600 mg, uključujući 50 to 600 mg, na primjer 100 mg ili 200mg.
Za bigvanid, prikladno doziranje metformina je između 100 do 3000 mg, na primjer 250, 500 mg, 850 mg ili 1000 mg.
Za inzulinski sekretagog, prikladna količina glibenklamida je u području od 2,5 do 20 mg, na primjer 10 mg ili 20 mg; prikladna količina glipizida je u području od 2,5 do 40 mg; prikladna količina gliklazida je u području od 40 do 320 mg ; prikladna količina tolazamida je u području od 100 to 1000 mg; prikladna količina tolbutamida je u području od 1000 to 3000 mg; prikladna količina klorpropamida je u području od 100 to 500 mg; i prikladna količina glikvidona je u području od 15 to 180 mg. Također, prikladna količina glimepirida je 1 do 6mg i prikladna količina glipentida je 2,5 do 20 mg.
Prikladna količina repaglinida je u području od 0.5 mg do 20 mg, na primjer 16 mg. Također, prikladna količina nateglinida je 90 do 360 mg, na primjer 270 mg.
U posebnom aspektu, pripravak sadržava 2 do 12 mg Spoja (I).
Prikladno je da pripravak sadržava 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12 mg Spoja (I).
Posebice, pripravak sadržava 2 do 4, 4 do 8 ili 8 do 12 mg Spoja (I).
Posebice, pripravak sadržava 2 do 4 mg Spoja (I).
Posebice, pripravak sadržava 4 do 8 mg Spoj (I).
Posebice, pripravak sadržava 8 do 12 mg Spoja (I).
Pogodno je da pripravak sadržava 2 mg Spoja (I).
Pogodno je da pripravak sadržava 4 mg Spoja (I).
Pogodno je da pripravak sadržava 8 mg Spoja (I).
Prikladno jedinično doziranje drugih inzulinskih senzitizatora uključuje doze od 100 do 800 mg troglitazona kao što su 200, 400, 600 ili 800mg ili doze od 5 do 50 mg uključujući 10 do 40 mg pioglitazona, kao što su 20, 30 ili 40 mg te također 15, 30 i 45 mg pioglitazona.
Prikladna doziranja drugih inzulinskih senzitizatora agonista PPARγ uključuju objavljene za agonist naveden u gore spomenutim patentnim prijavama, na primjer 2-(1-karboksi-2-{4-{2-(5-metil-2-fenil-oksazol-4-il)-etoksi]-fenil}-etilamino)-metil ester benzojeve kiseline i 2(S)-(2-benzoil-fenilamino)-3-{4-[2-(5-metil-2-fenil-oksazol-4-il)-etoksi]-fenil}-propionska kiselina je prikladno dozirana u skladu s doziranjem objavljenim u publikaciji WO 97/31907.
U liječenju se lijekovi mogu primjenjivati 1 do 6 puta na dan, ali najpogodnije je 1 ili 2 puta na dan.
Također, doza svake pojedine djelatne tvari u bilo kojem danom pripravku može, kao što se zahtijeva, varirati unutar poznatih zahtjevanih raspona doza, u odnosu na prihvaćen režim doziranja za taj spoj. Doze svake pojedine tvari također mogu biti prilagođene, kao što se zahtijeva, uzimajući u obzir povoljan učinak kombiniranja tvari kako je ovdje navedeno.
Podrazumijeva se da su inhibitor DPP-IV i drugi antidijabetik u farmaceutski prihvatljivom obliku, uključujući farmaceutski prihvatljive derivate kao što su njihove farmaceutski prihvatljive soli, esteri i solvati, prikladne za izabranu relevantnu farmaceutski aktivnu tvar. U nekim ovdje navedenim slučajevima nazivi koji se koriste za antidijabetike mogu se odnositi na određeni farmaceutski oblik relevantne djelatne tvari: Podrazumijeva se da su svi farmaceutski prihvatljivi oblici djelatnih tvari po sebi obuhvaćeni ovim izumom.
Ovaj izum također osigurava farmaceutski pripravak koji sadržava inhibitor dipeptidil peptidaze IV, drugi antidijabetik i farmaceutski prihvatljiv nosač, za primjenu kao terapijski aktivnu tvar.
Posebice, ovaj izum osigurava farmaceutski pripravak koji obuhvaća inhibitor dipeptidil peptidaze IV, drugi antidijabetik i farmaceutski prihvatljiv nosač za primjenu u liječenju dijabetesa melitusa, naročito tipa 2 dijabetesa i stanja povezanih s dijabetesom melitusom.
Obično su pripravci prilagođeni za oralnu primjenu. Međutim, mogu biti prilagođeni za druge načine primjene, na primjer parenteralnu primjenu, sublingvalnu ili transdermalnu primjenu.
Pripravci mogu biti u obliku tableta, kapsula, prašaka, granula, pastila, supozitorija, prašaka za pripremu otopine/suspenzije ili tekućih pripravaka, kao što su oralne ili sterilne parenteralne otopine ili suspenzije.
Za postizanje ujednačenosti primjene pogodno je da pripravak navedenog izuma bude u jediničnom obliku.
Jedinični oblici za oralnu primjenu mogu biti tablete ili kapsule i mogu ako je potrebno sadržavati uobičajene pomoćne tvari kao što su veziva, punila, lubrikanti, glidanti, sredstva za raspadanje i sredstva za vlaženje.
Kruti oralni pripravci mogu biti pripravljeni uobičajenim metodama miješanja, punjenja ili tabletiranja. Ponovljene operacije miješanja mogu se koristiti za potpuniju distribuciju djelatne tvari u pripravku koji ima veliku količinu punila. Takve su operacije naravno poznate u stanju tehnike. Tablete se mogu oblagati u skladu s metodama poznatim u normalnoj farmaceutskoj praksi, posebice ovojnicom koja se razgrađuje u crijevnom soku.
Tekući oralni pripravci mogu biti u obliku na primjer, emulzija, sirupa, ili eliksira, ili u obliku suhih preparata koji se prije primjene rekonstituiraju s vodom ili drugim prikladnim vehiklom. Takvi tekući pripravci mogu sadržavati uobičajene aditive kao što su sredstva za suspendiranje, na primjer sorbitol, sirup, metilceluloza, želatina, hidroksietilceluloza, karboksimetilceluloza, gel aluminij-stearata, hidrogenirane jestive masnoće; emulgatore, na primjer lecitin, sorbitan monooleat, ili arapska guma; nevodene vehikle (koji mogu uključivati jestiva ulja), na primjer bademovo ulje, frakcionirano kokosovo ulje, uljne estere kao što su esteri glicerola, propilen-glikola, ili etanola; konzervanse, na primjer metil ili propil p-hidroksibenzoat ili sorbinsku kiselinu; te ako je potrebno uobičajene korigense okusa ili boje.
Za parenteralnu primjenu, tekući jedinični oblici pripravljaju se od spoja i sterilnog vehikla, te ovisno o korištenoj koncentraciji, mogu biti suspendirani ili otopljeni u vehiklu. U pripravljanju otopina, spoj se može otopiti u vodi za injekcije i sterilizirati filtracijom prije punjenja u prikladne bočice ili ampule i zatvaranja. Pogodno je da pomoćne tvari kao što su lokalni anestetik, konzervans i pufer mogu biti otopljeni u vehiklu. U svrhu povećanja stabilnosti, pripravak može biti zamrznut nakon punjenja u bočicu i voda uklonjena pod vakuumom. Parenteralne suspenzije pripravljaju se u osnovi na isti način, osim što je djelatni spoj suspendiran umjesto otopljen u vehiklu, i sterilizacija ne može biti provedena filtracijom. Spoj može biti steriliziran izlaganjem etilen-oksidu prije suspendiranja u sterilnom vehiklu. Pogodno je da su sredstvo za povećanje površinske napetosti ili sredstvo za vlaženje u sastavu pripravka kako bi se omogućila ujednačena distribucija spoja.
Pripravci mogu sadržavati djelatnu tvar u količini od 0.1% do 99% masenih, pogodnije od 10-60% masenih, ovisno o načinu primjene.
Primjeri veziva uključuju arapsku gumu, alginsku kiselinu, kalcij-karboksimetilcelulozu, natrij-karboksimetilcelulozu, dekstrate, dekstrin, dekstrozu, etilcelulozu, želatinu, glukozni sirup, guar gumu, hidroksietilcelulozu, hidroksipropilcelulozu, hidroksipropilmetilcelulozu, magnezij aluminij-silikat, maltodekstrin, metilcelulozu, polimetakrilate, polivinilpirolidon, preželatinizirani škrob, natrij-alginat, sorbitol, škrob, sirup, tragakant.
Primjeri punila uključuju kalcij-karbonat, kalcij-fosfat, kalcij-sulfat, kalcij-karboksimetilcelulozu, natrij-karboksimetilcelulozu, šećer koji se može komprimirati, konzumni šećer, dekstrate, dekstrin, dekstrosu, dibazični kalcij-fosfat dihidrat, dibazični kalcij-fosfat, fruktozu, gliceril palmitostearat, glicin, hidrogenirano biljno ulje-tip 1, kaolin, laktozu, kukuruzni škrob, magnezij-karbonat, magnezij-oksid, maltodekstrin, manitol, mikrokristalnu celulozu, polimetakrilate, kalij-klorid, praškastu celulozu, preželatinizirani škrob, natrij-klorid, sorbitol, škrob, saharozu, šečerne pelete, talk, tribazični kalcij-fosfat, ksilitol.
Primjeri lubrikanata uključuju kalcij-stearat, gliceril monostearat, gliceril palmitostearat, magnezij-stearat, mikrokristalnu celulozu, natrij-benzoat, natrij-klorid, natrij-laurilsulfat, stearinsku kiselinu, natrij-stearilfumarat, talk, cink-stearat.
Primjeri glidanata uključuju koloidni silicij-dioksid, praškastu celulozu, magnezij-trisilikat, silicij-dioksid, talk.
Primjeri sredstava za raspadanje uključuju alginsku kiselinu, kalcij-karboksimetilcelulozu, natrij-karboksimetilcelulozu, koloidni silicij-dioksid, kroskarmelozu-natrij, krospovidon, guar gumu, magnezij aluminij-silikat, mikrokristalnu celulozu, metilcelulozu, polivinilpirolidon, kalij-polakrilin, preželatinizirani škrob, natrij-alginat, natrij-laurilsulfat, natrij škrob glikolat.
Primjer farmaceutski prihvatljivog sredstva za vlaženje je natrij-laurilsulfat.
Pripravci su pripravljeni i oblikovani u skladu s uobičajenim metodama, kao što su one obznanjene u standardnim referentnim tekstovima, na primjer Britanskoj i Američkoj farmakopeji, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (na primjer vidi 31. izdanje stranicu 341 i tamo citirane stranice) i Harry's Cosmeticology (Leonard Hill Books) ili gore spomenutim publikacijama.
Na primjer, kruti oralni pripravci mogu se pripraviti uobičajenim metodama miješanja, punjenja ili tabletiranja. Ponovljena operacija miješanja može se koristiti za potpuniju distribuciju djelatne tvari u pripravku koji ima veliku količinu punila. Takve su operacije naravno poznate u stanju tehnike. Tablete se mogu oblagati u skladu s dobro poznatim metodama u normalnoj farmaceutskoj praksi.
Pripravci mogu, ako je potrebno, biti u kutiji zajedno s pisanom ili otisnutom uputom za primjenu.
Očekuje se da pripravci i postupci opisani u ovom izumu nemaju nepovoljne toksikološke učinke u gore spomenutom području doziranja.
Farmakološki podaci
ZDF fa/fa štakori (Genetic Models, Inc., Indianapolis, IN) muškog spola, jednaki po starosti i masi smješteni su pojedinačno na 72°F i 50% relativne vlage sa 12-satnim ciklusima svjetlosti/mraka i hranjeni s PMI 5008 Formula Diet (PMI Nutrition International, Saint Louis, MO).
Životinje su dozirane oralno dva puta dnevno tijekom ciklusa mraka tijekom jednog tjedna s vehiklom (0.5% hidroksi-propilmetilceluloza (HPMC) i 0.1% Tween 80), 100 mg/kg izoleucin tiazolidida (Spoj (II)), 5 mg/kg Spoja (I) u vehiklu, ili 5 mg/kg Spoja (I) sa 100 mg/kg Spoja (II) u vehiklu.
Za mjerenje tolerancije na glukozu, štakori su tretirani ispitivanim spojem 7 dana uz davanje intraperitonealne injekcije otopine glukoze u fiziološkoj otopini 30 minuta nakon posljednje doze ispitivanog spoja.
Štakori su anestezirani izofluranom u svrhu skupljanja krvi iz srca 30 minuta nakon primjene otopine glukoze. Kemijska mjerenja seruma provedena su korištenjem automatiziranog kemijskog analizatora (ILab600, Instrument Laboratory, Lexington, MA).
Aktivnost DPP-IV mjerena je korištenjem fluorogenskog supstrata Gly-Pro-AMC (50 mM) u skladu s proizvođačevim specifikacijama (Enzyme System Products, Livermore CA). Supstrat je pomiješan s 50 mM Trisa, uz pH 7.8 u plazmi (20% konačnih v/v), te su uzorci inkubirani 5-20 min pri 30°C. Aktivnost DPP-IV određena je mjerenjem fluorescencije korištenjem citofluor spectrofluorometra s filterima podešenim na 360 nm za ekscitaciju i 460 nm za emisiju.
Rezultati svake grupe (n=6) iskazani su prosječno i uspoređeni sa rezultatima za štakore tretirane vehiklom kako bi se odredila signifikantnost te su prikazani u tablici I.
Slijedeći podaci prikazuju ovaj izum ali ga ne ograničavaju ni na koji način.
TABLICA I
ZDF štakori, tretirani BID-om tijekom 7 dana
[image]
*P.0.05
Claims (14)
1. Postupak za liječenje dijabetesa melitusa, naročito dijabetesa tipa 2 i stanja povezanih s dijabetesom melitusom kod sisavaca kao što je čovjek, naznačena time da se sastoji od primjene učinkovite, netoksične i farmaceutski prihvatljive količine inhibitora dipeptidil peptidaze IV i drugog antidijabetika sisavcima kojima je to potrebno.
2. Postupak prema zahtjevu 1, naznačen time da je dipeptidil peptidaza IV izabrana iz: L-treo-izoleucil pirolidida, L-alo-izoleucil tiazolidida, L-alo-izoleucil pirolidida i njihovih soli ili 1[2-[(5-cijanopiridin-2-il)aminoetilamino]acetil-2-cijano-(S)-pirolidin i (2S)-1-[(2S)-2-amino-3,3-dimetilbutanoil]-2-pirolidinkarbonitril.
3. Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da drugi antidijabetik obuhvaća jedan ili više inhibitora alfa glukozidaze, bigvanida, inzulinskih sekretagoga ili inzulinskih senzitizatora.
4. Postupak prema zahtjevu 3, naznačen time da je inhibitor alfa glukozidaze izabran iz skupine koju čine akarboza, emiglitat, miglitol i vogliboza.
5. Postupak prema zahtjevu 3 naznačen time da je bigvanid izabran iz skupine koju čine metformin, buformin i fenformin.
6. Postupak prema zahtjevu 3, naznačen time da je inzulinski sekretagog sulfonilureja izabrana iz skupine koju čine: glibenklamid, glipizid, gliklazid, glimepirid, tolazamid i tolbutamid, acetoheksamid, karbutamid, klorpropamid, glibornurid, glikvidon, glizentid, glizolamid, glizoksepid, gliklopiamid, glicilamid i glipentid.
7. Postupak prema zahtjevu 3, naznačen time da je inzulinski sekretagog repaglinid ili nateglinid.
8. Postupak prema zahtjevu 3, naznačen time da je inzulinski senzitizator tiazolidindion.
9. Postupak prema zahtjevu 7, naznačen time da je tiazolidindion izabran iz skupine koju čine: (+)-5-([4-[(3,4-dihidro-6-hidroksi-2,5,7,8-tetrametil-2H-1-benzopiran-2-il)metoksi]fenil]metil]-2,4-tiazolidindion (ili troglitazon), 5-[4-[(1-metilcikloheksil)metoksi]benzil]tiazolidin-2,4-dione (ili ciglitazon), 5-[4-[2-(5-etilpiridin-2-il)etoksi]benzil tiazolidin-2,4-dion (ili pioglitazon) ili 5-[(2-benzil-2,3-dihidrobenzopiran)-5-ilmetil)tiazolidin-2,4-dion (ili englitazon).
10. Postupak prema zahtjevu 7, naznačen time da je tiazolidindion 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi] benzil]tiazolidin-2,4-dion, 5-[4-[2-(5-etilpiridin-2-il)etoksi]benzil]tiazolidin-2,4-dion (ili pioglitazon); ili njihov farmaceutski prihvatljiv derivat.
11. Farmaceutski pripravak, naznačen time da sadržava inhibitor dipeptidil peptidaze IV i drugi antidijabetik te farmaceutski prihvatljiv nosač.
12. Postupak za izradu farmaceutskog pripravka, naznačen time da sadržava inhibitor dipeptidil peptidaze IV, drugi antidijabetik i farmaceutski prihvatljiv nosač, a obuhvaća miješanje inhibitora dipeptidil peptidaze IV, drugog antidijabetika i farmaceutski prihvatljivog nosača.
13. Farmaceutski pripravak, naznačen time da sadržava inhibitor dipeptidil peptidaze IV, drugi antidijabetik i farmaceutski prihvatljiv nosač za primjenu kao aktivna terapijska supstancija.
14. Farmaceutski pripravak, naznačen time da sadržava inhibitor dipeptidil peptidaze IV, drugi antidijabetik i farmaceutski prihvatljiv nosač za primjenu u liječenju dijabetesa melitusa, naročito dijabetesa tipa 2 i stanja povezanih s dijabetesom melitusom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0014969.0A GB0014969D0 (en) | 2000-06-19 | 2000-06-19 | Novel method of treatment |
PCT/GB2001/002696 WO2001097808A1 (en) | 2000-06-19 | 2001-06-19 | Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20020994A2 true HRP20020994A2 (en) | 2005-02-28 |
Family
ID=9893956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20020994A HRP20020994A2 (en) | 2000-06-19 | 2002-12-12 | Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus |
Country Status (29)
Country | Link |
---|---|
US (2) | US7241756B2 (hr) |
EP (2) | EP1292300B1 (hr) |
JP (1) | JP2003535898A (hr) |
KR (1) | KR20030019440A (hr) |
CN (1) | CN1443068A (hr) |
AP (1) | AP2002002703A0 (hr) |
AT (1) | ATE419850T1 (hr) |
AU (3) | AU2001264148A1 (hr) |
BG (1) | BG107385A (hr) |
BR (1) | BR0111800A (hr) |
CA (1) | CA2413299A1 (hr) |
CZ (1) | CZ20024069A3 (hr) |
DE (1) | DE60137329D1 (hr) |
DZ (1) | DZ3390A1 (hr) |
EA (1) | EA200300036A1 (hr) |
EC (1) | ECSP024397A (hr) |
GB (1) | GB0014969D0 (hr) |
HR (1) | HRP20020994A2 (hr) |
HU (1) | HUP0301194A3 (hr) |
IL (2) | IL153529A0 (hr) |
MA (1) | MA25820A1 (hr) |
MX (1) | MXPA02012763A (hr) |
NO (1) | NO20026038L (hr) |
OA (1) | OA12295A (hr) |
PL (1) | PL360493A1 (hr) |
SK (1) | SK17832002A3 (hr) |
WO (1) | WO2001097808A1 (hr) |
YU (1) | YU1703A (hr) |
ZA (1) | ZA200300203B (hr) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
EP1399470A2 (en) * | 2001-06-27 | 2004-03-24 | Probiodrug AG | Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
ES2278944T3 (es) | 2002-02-28 | 2007-08-16 | Prosidion Ltd. | Inhibidores de dpiv basados en glutaminilo. |
AU2007203210B2 (en) * | 2002-05-29 | 2009-10-01 | Novartis Ag | Combination of a DPP IV inhibitor and a cardiovascular compound |
GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
JP4233524B2 (ja) * | 2002-08-21 | 2009-03-04 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 8−[3−アミノ−ピペリジン−1−イル]−キサンチン、その製造およびその薬理組成物としての使用 |
AU2003293311A1 (en) * | 2002-09-18 | 2004-04-23 | Prosidion Ltd. | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
BR0314655A (pt) * | 2002-09-26 | 2005-08-02 | Eisai Co Ltd | Droga de combinação |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
NZ544307A (en) * | 2003-06-27 | 2008-12-24 | Reddy Research Foundation | Compositions comprising balaglitazone and further antidiabetic compounds |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN1867560A (zh) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
CN1292747C (zh) * | 2003-09-16 | 2007-01-03 | 广东省心血管病研究所 | 一种用于治疗高血压的复方制剂 |
EP2289498A1 (en) | 2003-10-15 | 2011-03-02 | Probiodrug AG | Use of inhibitors of glutaminyl clyclase |
KR20060109922A (ko) * | 2003-10-31 | 2006-10-23 | 알자 코포레이션 | 가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형 |
KR20150028829A (ko) | 2003-11-17 | 2015-03-16 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
ES2940341T3 (es) | 2004-01-20 | 2023-05-05 | Novartis Ag | Formulación y proceso de compresión directa |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
EP1782832A4 (en) * | 2004-08-26 | 2009-08-26 | Takeda Pharmaceutical | MEANS FOR THE TREATMENT OF DIABETES |
BRPI0518409A2 (pt) * | 2004-10-25 | 2008-11-18 | Novartis Ag | combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
JP2008115080A (ja) * | 2005-04-22 | 2008-05-22 | Taisho Pharmaceutical Co Ltd | 併用医薬 |
ES2390231T3 (es) | 2005-06-03 | 2012-11-07 | Mitsubishi Tanabe Pharma Corporation | Agentes farmacéuticos concomitantes y su uso |
GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DK1942898T4 (da) | 2005-09-14 | 2014-06-02 | Takeda Pharmaceutical | Dipeptidylpeptidase-inhibitorer til behandling af diabetes |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
WO2007035665A1 (en) * | 2005-09-20 | 2007-03-29 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
TW200738266A (en) * | 2005-09-29 | 2007-10-16 | Sankyo Co | Pharmaceutical agent containing insulin resistance improving agent |
US8414921B2 (en) | 2005-12-16 | 2013-04-09 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
UA95789C2 (ru) * | 2005-12-28 | 2011-09-12 | Такеда Фармасьютикал Компани Лимитед | Средство для защиты поджелудочной железы и его применение |
JP5094416B2 (ja) * | 2005-12-28 | 2012-12-12 | 武田薬品工業株式会社 | 糖尿病治療剤 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CA2677201C (en) * | 2007-02-01 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and pioglitazone |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
NZ583346A (en) | 2007-07-19 | 2012-02-24 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and metformin hydrochloride |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
WO2009128360A1 (ja) * | 2008-04-18 | 2009-10-22 | 大日本住友製薬株式会社 | 糖尿病治療剤 |
DK2275108T3 (da) * | 2008-05-14 | 2014-09-08 | Sanwa Kagaku Kenkyusho Co | Farmaceutisk præparat omfattende en dpp-iv-inhibitor og et andet diabetes-terapimiddel i konkomitant eller kombineret form |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101054911B1 (ko) * | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
AU2010308433A1 (en) * | 2009-10-23 | 2012-06-07 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
AU2011237775A1 (en) | 2010-04-06 | 2012-11-22 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
CN102971005A (zh) | 2010-06-24 | 2013-03-13 | 贝林格尔.英格海姆国际有限公司 | 糖尿病治疗 |
CN103539791B (zh) | 2010-09-22 | 2017-01-11 | 艾尼纳制药公司 | Gpr119 受体调节剂和对与其相关的障碍的治疗 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
TW201636015A (zh) * | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
CN115109161B (zh) * | 2022-06-28 | 2023-08-11 | 广东赛尔生物科技有限公司 | 含有间充质干细胞的减肥药物组合物 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
DK173350B1 (da) | 1985-02-26 | 2000-08-07 | Sankyo Co | Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem |
JPH06779B2 (ja) | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
US4812570A (en) | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
SG59988A1 (en) | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
US4791125A (en) | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
WO1989008651A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
US5061717A (en) | 1988-03-08 | 1991-10-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
AU650465B2 (en) | 1990-07-03 | 1994-06-23 | Yamanouchi Pharmaceutical Co., Ltd. | Bisheterocyclic compound |
DE69106714T2 (de) | 1990-08-23 | 1995-05-11 | Pfizer | Hypoglykämische hydroxyharnstoffderivate. |
JPH04210683A (ja) | 1990-12-06 | 1992-07-31 | Terumo Corp | チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬 |
SK109993A3 (en) | 1991-04-11 | 1994-12-07 | Upjohn Co | Thiazolidinedione derivatives producing and use thereof |
US5183823A (en) | 1991-04-11 | 1993-02-02 | Takeda Chemical Industries, Ltd. | Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents |
TW222626B (hr) | 1991-07-22 | 1994-04-21 | Pfizer | |
FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5264451A (en) | 1992-04-07 | 1993-11-23 | American Home Products Corporation | Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones |
AU3959193A (en) | 1992-04-10 | 1993-11-18 | Smithkline Beecham Plc | Heterocyclic compounds and their use in the treatment of type II-diabetes |
WO1993022445A1 (en) | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
PL176885B1 (pl) | 1992-07-03 | 1999-08-31 | Smithkline Beecham Plc | Kompozycja farmaceutyczna |
US5232945A (en) | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
US5478852C1 (en) | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
AU4721897A (en) | 1996-10-25 | 1998-05-22 | Tanabe Seiyaku Co., Ltd. | Tetrahydroisoquinoline derivatives |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US6274608B1 (en) * | 1999-04-20 | 2001-08-14 | Novo Nordisk A/S | Compounds, their preparation and use |
US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
SG149676A1 (en) * | 1999-12-23 | 2009-02-27 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
ATE346613T1 (de) * | 2000-01-21 | 2006-12-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
US7078397B2 (en) * | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
-
2000
- 2000-06-19 GB GBGB0014969.0A patent/GB0014969D0/en not_active Ceased
-
2001
- 2001-06-19 HU HU0301194A patent/HUP0301194A3/hu unknown
- 2001-06-19 CZ CZ20024069A patent/CZ20024069A3/cs unknown
- 2001-06-19 OA OA1200200388A patent/OA12295A/en unknown
- 2001-06-19 WO PCT/GB2001/002696 patent/WO2001097808A1/en active Application Filing
- 2001-06-19 AP APAP/P/2002/002703A patent/AP2002002703A0/en unknown
- 2001-06-19 YU YU1703A patent/YU1703A/sh unknown
- 2001-06-19 IL IL15352901A patent/IL153529A0/xx unknown
- 2001-06-19 CA CA002413299A patent/CA2413299A1/en not_active Abandoned
- 2001-06-19 KR KR1020027017279A patent/KR20030019440A/ko not_active Application Discontinuation
- 2001-06-19 PL PL36049301A patent/PL360493A1/xx unknown
- 2001-06-19 CN CN01813126A patent/CN1443068A/zh active Pending
- 2001-06-19 EP EP01938472A patent/EP1292300B1/en not_active Expired - Lifetime
- 2001-06-19 DZ DZ013390A patent/DZ3390A1/xx active
- 2001-06-19 JP JP2002503292A patent/JP2003535898A/ja not_active Withdrawn
- 2001-06-19 EP EP08168689A patent/EP2036554A1/en not_active Withdrawn
- 2001-06-19 BR BR0111800-5A patent/BR0111800A/pt not_active Application Discontinuation
- 2001-06-19 SK SK17832002A patent/SK17832002A3/sk not_active Application Discontinuation
- 2001-06-19 DE DE60137329T patent/DE60137329D1/de not_active Expired - Fee Related
- 2001-06-19 AU AU2001264148A patent/AU2001264148A1/en not_active Abandoned
- 2001-06-19 AT AT01938472T patent/ATE419850T1/de not_active IP Right Cessation
- 2001-06-19 EA EA200300036A patent/EA200300036A1/ru unknown
- 2001-06-19 MX MXPA02012763A patent/MXPA02012763A/es active IP Right Grant
-
2002
- 2002-12-12 HR HR20020994A patent/HRP20020994A2/hr not_active Application Discontinuation
- 2002-12-12 BG BG107385A patent/BG107385A/bg unknown
- 2002-12-16 NO NO20026038A patent/NO20026038L/no not_active Application Discontinuation
- 2002-12-18 MA MA26965A patent/MA25820A1/fr unknown
- 2002-12-19 EC EC2002004397A patent/ECSP024397A/es unknown
-
2003
- 2003-01-08 ZA ZA200300203A patent/ZA200300203B/en unknown
-
2005
- 2005-11-11 AU AU2005232303A patent/AU2005232303A1/en not_active Abandoned
-
2006
- 2006-06-01 US US11/421,548 patent/US7241756B2/en not_active Expired - Fee Related
-
2007
- 2007-06-05 US US11/758,259 patent/US20070238756A1/en not_active Abandoned
- 2007-12-27 IL IL188471A patent/IL188471A0/en unknown
-
2008
- 2008-09-08 AU AU2008212061A patent/AU2008212061A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020994A2 (en) | Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus | |
US7078397B2 (en) | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus | |
EA003144B1 (ru) | Способ лечения диабета тиазолидиндионом и метформином | |
JP2005213273A (ja) | チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療 | |
JP2005247865A (ja) | チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療 | |
US20050054687A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
UA67743C2 (uk) | Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету | |
SK612000A3 (en) | Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition | |
CA2350062A1 (en) | Combinations comprising a beta-agonist and a further antidiabetic agent | |
NZ501345A (en) | Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent | |
US20010034356A1 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor | |
CZ2000172A3 (cs) | Léčivo pro léčbu diabetes mellitus a stavů s diabetes mellitus spojených a farmaceutický prostředek | |
MXPA00000655A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
MXPA00000631A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
MXPA00000633A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040503 Year of fee payment: 4 |
|
A1OB | Publication of a patent application | ||
OBST | Application withdrawn |